Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

被引：20
|
作者：
Kelley, Michael J. [1 ,2 ,3 ]
Jha, Gautam [4 ]
Shoemaker, Debra [2 ]
Herndon, James E., II [2 ]
Gu, Lin [2 ]
Barry, William T. [2 ,5 ]
Crawford, Jeffrey [1 ,2 ]
Ready, Neal [1 ,2 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA
[3] Durham Vet Affairs Med Ctr, Med Serv, Durham, NC USA
[4] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
[5] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
来源：
CANCER INVESTIGATION | 2017年 / 35卷 / 01期
关键词：
Non-small cell lung cancer; Src; gene expression; ERLOTINIB; TRIAL;
D O I：
10.1080/07357907.2016.1253710
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients hadminor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.
引用
收藏
页码：32 / 35
页数：4
相关论文
共 50 条
  • [1] Phase II study of dasatinib in patients with advanced non-small cell lung cancer
    Johnson, F. M.
    Bekele, B. N.
    Feng, L.
    Wistuba, I. I.
    Tang, X.
    Tran, H. T.
    Erasmus, J. J.
    Hwang, L.
    Takebe, N.
    Stewart, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
    Clement-Duchene, Christelle
    Natale, Ronald B.
    Jahan, Thierry
    Krupitskaya, Yelena
    Osarogiagbon, Raymond
    Sanborn, Rachel E.
    Bernstein, Eric D.
    Dudek, Arkadiusz Z.
    Latz, Jane E.
    Shi, Peipei
    Wakelee, Heather A.
    LUNG CANCER, 2012, 78 (01) : 57 - 62
  • [3] A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
    Gerena-Lewis, Margie
    Crawford, Jeffrey
    Bonomi, Philip
    Maddox, Ann Marie
    Hainsworth, John
    McCune, David E.
    Shukla, Rakesh
    Zeigler, Haoyue
    Hurtubise, Paul
    Chowdhury, Tracy R.
    Fletcher, Brandon
    Dyehouse, Karyn
    Ghalie, Richard
    Jazieh, Abdul R.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (03): : 269 - 273
  • [4] A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer
    Komiya, Takefumi
    Memmott, Regan M.
    Blumenthal, Gideon M.
    Bernstein, Wendy
    Ballas, Marc S.
    De Chowdhury, Roopa
    Chun, Guinevere
    Peer, Cody J.
    Figg, William D.
    Liewehr, David J.
    Steinberg, Seth M.
    Giaccone, Giuseppe
    Szabo, Eva
    Kawabata, Shigeru
    Tsurutani, Junji
    Rajan, Arun
    Dennis, Phillip A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (03) : 247 - +
  • [5] A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer
    Heist, Rebecca Suk
    Fidias, Panos
    Huberman, Mark
    Ardman, Blair
    Sequist, Lecia V.
    Temel, Jennifer S.
    Lynch, Thomas J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (10) : 1153 - 1158
  • [6] Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
    Kim, Young Saing
    Cho, Eun Kyung
    Woo, Hyun Sun
    Hong, Junshik
    Ahn, Hee Kyung
    Park, Inkeun
    Sym, Sun Jin
    Kyung, Sun Young
    Kang, Shin Myung
    Park, Jeong-Woong
    Jeong, Sung Hwan
    Park, Jinny
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 80 - 87
  • [7] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [8] Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    S Novello
    G V Scagliotti
    R Rosell
    M A Socinski
    J Brahmer
    J Atkins
    C Pallares
    R Burgess
    L Tye
    P Selaru
    E Wang
    R Chao
    R Govindan
    British Journal of Cancer, 2009, 101 : 1543 - 1548
  • [9] Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
    Novello, S.
    Scagliotti, G. V.
    Rosell, R.
    Socinski, M. A.
    Brahmer, J.
    Atkins, J.
    Pallares, C.
    Burgess, R.
    Tye, L.
    Selaru, P.
    Wang, E.
    Chao, R.
    Govindan, R.
    BRITISH JOURNAL OF CANCER, 2009, 101 (09) : 1543 - 1548
  • [10] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345